Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

MorphoSys AG (MOR)

4.46   -0.17 (-3.67%) 09-24 15:44
Open: 4.57 Pre. Close: 4.63
High: 4.57 Low: 4.45
Volume: 37,812 Market Cap: 596(M)
MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma. The company also develops Pelabresib, a small molecule that is in Phase II clinical trial to treat myelofibrosis; Felzartamab, an antibody directed against CD38, which is in Phase I/II clinical trials for the treatment of anti-PLA2R-positive membranous nephropathy, an autoimmune disease; and CPI-0209, a small molecule that is in Phase I/II designed to promote anti-tumor activity by inhibiting EZH2. In addition, it develops Gantenerumab, an antibody for the treatment of Alzheimer's diseases through its pharmaceutical partners; Otilimab, an antibody for rheumatoid arthritis; Tremfya, an antibody to treat psoriasis, psoriatic arthritis, and palmoplantar pustulosis; and MOR210/TJ210, an antibody to treat immuno-oncology and autoimmune diseases. MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize felzartamab in China, Taiwan, Hong Kong, and Macau; a strategic alliance with the LEO Pharma; a joint collaboration and license agreement with Incyte Corporation to develop and commercialize MorphoSys investigational compound tafasitamab; and a clinical collaboration with Incyte Corporation and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was founded in 1992 and is headquartered in Planegg, Germany.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 4.6 - 4.64 4.64 - 4.67
Low: 4.36 - 4.41 4.41 - 4.45
Close: 4.39 - 4.49 4.49 - 4.54

Technical analysis

as of: 2022-09-23 4:25:58 PM
Overall:       
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 5.63     One year: 6.17
Support: Support1: 4.07    Support2: 3.39
Resistance: Resistance1: 4.82    Resistance2: 5.28
Pivot: 4.73
Moving Average: MA(5): 4.75     MA(20): 4.65
MA(100): 5.14     MA(250): 7.2
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 44.6     %D(3): 56
RSI: RSI(14): 39.4
52-week: High: 12.44  Low: 4.07
Average Vol(K): 3-Month: 39 (K)  10-Days: 61 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ MOR ] has closed above bottom band by 31.1%. Bollinger Bands are 15% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Fri, 23 Sep 2022
Jennifer Hudson Show Sweepstakes - Tampa - MOR-TV.com

Thu, 22 Sep 2022
MOR Is Auckland's New Online Micro-Bakery Delivering Fresh Croissants Right to Your Door This Weekend - Concrete Playground

Thu, 22 Sep 2022
Should You Sell Morphosys Ag (MOR) Stock Thursday Morning? - InvestorsObserver

Wed, 21 Sep 2022
‘Andor’ Episode 3 Recap: A Visually Stunning Firefight & Cassian Joins the Rebellion - TV Insider

Wed, 21 Sep 2022
'Andor' brings back a brilliant concept from 1970s Star Wars canon - Inverse

Sun, 18 Sep 2022
Soccer vs Southern Indiana on 9/18/2022 - Box Score - MSU Eagles

Financial Analysis

Price to Book Value: Underperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Outperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Underperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 137 (M)
Shares Float 131 (M)
% Held by Insiders 0 (%)
% Held by Institutions 2 (%)
Shares Short 119 (K)
Shares Short P.Month 143 (K)

Stock Financials

EPS 0.89
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 4.73
Profit Margin (%) 0
Operating Margin (%) -168.6
Return on Assets (ttm) -9
Return on Equity (ttm) -165.2
Qtrly Rev. Growth -12.2
Gross Profit (p.s.) 1.07
Sales Per Share 1.27
EBITDA (p.s.) -2.1
Qtrly Earnings Growth 0
Operating Cash Flow -583 (M)
Levered Free Cash Flow -226 (M)

Stock Valuations

PE Ratio 4.98
PEG Ratio 0
Price to Book value 0.94
Price to Sales 3.5
Price to Cash Flow -1.05

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.